TY - JOUR
T1 - Once-daily prolonged-release tacrolimus versus twice-daily tacrolimus in liver transplantation
AU - Huang, Bingsong
AU - Liu, Jun
AU - Li, Jun
AU - Schroder, Paul M.
AU - Chen, Maogen
AU - Deng, Ronghai
AU - Deng, Suxiong
N1 - Publisher Copyright:
© 2019
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Objective: For patients who have received a kidney transplant, studies have shown that once-daily prolonged-release tacrolimus (TAC) has similar efficacy and safety to standard twice-daily dosing. The purpose of this study was to perform a meta-analysis to compare the effectiveness and safety of daily TAC (TAC qd) versus standard twice-daily TAC (TAC bid) administration in liver transplantation (LT). Design: Meta-analysis. Setting and participants: We systematically searched the PubMed/MEDLINE, Web of Science, and Cochrane Library databases for studies comparing outcomes of LT patients who received TAC qd versus TAC bid. Outcome measures: Results were reported as odds ratios (ORs) with 95% CIs. Results: Six studies, which included 5179 LT recipients (TAC qd = 951; TAC bid = 4228) were included in the analysis. The TAC qd group had a low 1-year graft loss rate (OR 0.70 [95% CI 0.54–0.91], P = 0.008) and lower rate of biopsy-proven acute rejection (BPAR) at 90 days (OR 0.46 [95% CI 0.24–0.89], P = 0.02) compared with the TAC bid group. There was no significant difference in 1-year mortality or the incidence of adverse events after LT between the 2 groups. Conclusions: Current evidence suggests that TAC qd is safe and effective for LT patients during the first year after transplantation. Longer-term follow-up studies are necessary to determine if TAC qd is safe and effective beyond the first year after LT.
AB - Objective: For patients who have received a kidney transplant, studies have shown that once-daily prolonged-release tacrolimus (TAC) has similar efficacy and safety to standard twice-daily dosing. The purpose of this study was to perform a meta-analysis to compare the effectiveness and safety of daily TAC (TAC qd) versus standard twice-daily TAC (TAC bid) administration in liver transplantation (LT). Design: Meta-analysis. Setting and participants: We systematically searched the PubMed/MEDLINE, Web of Science, and Cochrane Library databases for studies comparing outcomes of LT patients who received TAC qd versus TAC bid. Outcome measures: Results were reported as odds ratios (ORs) with 95% CIs. Results: Six studies, which included 5179 LT recipients (TAC qd = 951; TAC bid = 4228) were included in the analysis. The TAC qd group had a low 1-year graft loss rate (OR 0.70 [95% CI 0.54–0.91], P = 0.008) and lower rate of biopsy-proven acute rejection (BPAR) at 90 days (OR 0.46 [95% CI 0.24–0.89], P = 0.02) compared with the TAC bid group. There was no significant difference in 1-year mortality or the incidence of adverse events after LT between the 2 groups. Conclusions: Current evidence suggests that TAC qd is safe and effective for LT patients during the first year after transplantation. Longer-term follow-up studies are necessary to determine if TAC qd is safe and effective beyond the first year after LT.
UR - http://www.scopus.com/inward/record.url?scp=85072029745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072029745&partnerID=8YFLogxK
U2 - 10.1016/j.japh.2019.08.002
DO - 10.1016/j.japh.2019.08.002
M3 - Article
C2 - 31521585
AN - SCOPUS:85072029745
SN - 1544-3191
VL - 59
SP - 816-823.e2
JO - Journal of the American Pharmacists Association
JF - Journal of the American Pharmacists Association
IS - 6
ER -